Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly silence any target gene of interest. The clinical application of siRNA requires the use of safe and effective delivery systems. In this study, we investigated the use of non-ionic surfactant vesicles (NISV) for the delivery of siRNA. Different types of NISV formulations were synthesised by microfluidic mixing and then evaluated for their physiochemical properties and cytotoxicity. The ability of the NISV to carry and transfect siRNA targeting green fluorescent protein (GFP) into A549 that stably express GFP (copGFP-A549) was evaluated.
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Introduction
The discovery of the RNA interference (RNAi) mechanism by Fire et al. represents one of the most significant advances in molecular biology. This mechanism is an endogenous posttranscriptional gene regulatory process that involves the degradation of messenger RNA (mRNA) in a highly sequence-specific manner [1] . Double-stranded (ds) small interfering RNA (siRNA), composed of 21-23 base pairs in length, can induce RNAi and interfere with the expression of the protein of the target RNA [2] . The RNAi mechanism involves the incorporation of the anti-sense strand of the siRNA into the RNA-induced silencing complex in the cytoplasm, followed by cleavage of the target mRNA that is complementary to the antisense strand of the siRNA to cause silencing of the gene encoded by that mRNA [3] .
Following this discovery, a significant body of research has been carried out to investigate the application of RNAi for the treatment of human diseases [4, 5] . For therapeutic applications, synthetic siRNA can be designed to target overexpressed genes in human diseases such as cancer [6] . The potential application of siRNA therapeutics has been demonstrated in different types of cancer, including bladder, ovarian, lung, and prostate cancers [7] [8] [9] [10] . However, the successful application of siRNA-based therapeutics is dependent on the efficient delivery of siRNA to target cells [11] . Naked siRNA has a very short half-life as a result of rapid degradation and elimination from the blood by nucleases [12] . Moreover, the negative charge of siRNA molecules prevents their passive diffusion across hydrophobic cellular membranes in addition to creating electrostatic repulsion with negatively charged cellular membrane proteins [13] . Due to the poor stability of siRNA in physiological fluids and inefficient cellular uptake, effective delivery of therapeutic siRNA into the cytoplasm of target cells is one of the main challenges in the development of siRNAbased treatments [14] . An ideal siRNA delivery system, for clinical application, should protect the siRNA from rapid digestion, efficiently deliver the therapeutic siRNA into the target cells, and promote the subsequent release of siRNA from endosome vesicles into the cytoplasm, where they can be loaded into the silencing complex for gene silencing.
Moreover, the delivery system should be biodegradable with low toxicity.
Non-viral delivery systems such as liposomes, dendrimers, cell-penetration peptides, and many others have been investigated for the delivery of siRNA to expand their clinical application [15] . Lipid-based nanoparticles such as liposomes are by far the most studied drug-delivery system for this purpose. However, due to the limitations of liposomes, such as cost and stability, the delivery of siRNA by non-ionic surfactant vesicles (NISV) have been investigated as an alternative. NISV are lipid-based nanoparticles, which are composed of non-ionic surfactants, cholesterol, and charged lipids. These components self-assemble upon hydration into a bilayer structure enclosing an aqueous core similar to liposomes [16] . NISV are generally superior to liposomes in terms of stability and production costs [17] . Different types of surfactant can be used in NISV formulations such as Tweens, Spans, Brijs, and many others [18] . NISV have been widely investigated as drug delivery systems due to their potential to carry and encapsulate a variety of therapeutic agents. However, the application of NISV in the field of gene delivery has not been investigated extensively. In terms of nucleic acid delivery, most of the research in the literature use these vesicles for DNA delivery [19, 20] , and there is only a limited number of publications describing their use for siRNA delivery [21] [22] [23] .
Previously, stable NISV through microfluidics were formulated [18] . In this study, we have synthesised cationic NISV (CN) using microfluidics with different surfactants and investigated their potential application for siRNA transfection. The cationic charge on the formulated NISV was achieved using the cationic lipid didodecyldimethylammonium bromide (DDAB), which not only helps with constructing the NISV bilayer structure, but also offers positive charge to both bind siRNA drugs and mediate cellular uptake via electrostatic adhesion to cellular surfaces that carry a slight negative charge. The prepared CN were evaluated for their physical characteristics, cytotoxicity, and transfection efficiency.
Results were compared against a commercially available transfecting reagent, HiPerFect (Qiagen, UK).
Materials and Methods
Materials
Monopalmitin glycerol (Monohexadecanoin) (MPG) was purchased from Larodan Fine Chemicals AB (Sweden). Cholesterol (Chol); polyoxyethylenesorbitan trioleate (Tween 85); DDAB; resazurin powder; Tris base; sodium pyrophosphate (Na4P2O7); sodium dodecyl sulphate (SDS); bromophenol blue; glycerol; glycine; sodium chloride (NaCl); bovine serum albumin (BSA); ethylenediamine tetra-acetic acid (EDTA); Tween 20; Dulbecco's Modified Eagles medium (DMEM); L-glutamine; and penicillin-streptomycin were purchased from Sigma-Aldrich (UK). Foetal bovine serum (FBS) was purchased from Biosera (UK). Sodium pyruvate (100mM) and minimum essential medium non-essential amino acids (MEM NEAA) were purchased from Life Technologies (UK). Skimmed milk powder was purchased from Premier Foods Ltd (UK). The human non-small cell lung cancer (A549) cell line was purchased from the American Type Culture Collection (ATCC®). Human non-small cell lung cancer A549 cells that stably express Green Fluorescent Protein (copGFP-A549) were purchased from Cell Biolabs, Inc., (UK). Sterile, RNase-free phosphate buffered saline 1M and sterile RNase-free water were purchased from LONZA (UK). AllStars AF488-labelled Negative Control siRNA and HiPerFect transfecting reagent were purchased from Qiagen (UK). The anti-GFP DsiRNA (siGFP) duplex sequence (1) , and the non-targeting scrambled DsiRNA (2) ( Table 1) were synthesised by Integrated DNA Technologies (Belgium). A rabbit polyclonal antibody against copGFP was purchased from Evrogen JSC (Russia) and a rabbit polyclonal antibody against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was purchased from Santa Cruz Biotechnology (UK). 
Formulation of cationic NISV (CN)
CN were prepared by microfluidics as described previously [18] using a NanoAssemblr TM (Benchtop, Precision NanoSystems Inc., Canada). Three different CN formulations (A-C)
were prepared ( Table 2 ). To prepare the CN, the required lipid components at the desired ratios were dissolved in ethanol at a final lipid concentration of 10 mg/ml. The lipid phase was then injected into the first inlet and the aqueous buffer (sterile RNase-free water) into the second inlet of the microfluidic microchannel using disposable syringes. CN were formulated at a total flow rate of 12 ml/min and a volumetric flow rate ratio of 3:1 between the aqueous and lipid phase at 50ºC. The resulting CN dispersions collected from the outlet stream were immediately diluted with sterile RNase-free water in order to reduce the final ethanol content in the preparation to 6.25% (v/v). 
CN characterisation
Particle size, polydispersity index (PDI), and zeta potential (ZP) of the CN formulations were measured by dynamic light scattering (DLS) using a Zetasizer Nano-ZS (Malvern Instruments, UK). The samples were diluted in distilled water at a 1/20 dilution and the measurements were taken at 25°C.
Stability studies of CN
CN colloidal systems were tested for their stability over a two month storage at room temperature (25°C) in a controlled temperature room. ZAverage, PDI, and ZP were measured every week. 
Cytotoxicity of CN formulations
Preparation of CN/siRNA nioplexes
CN/siRNA complexes (termed nioplexes) were prepared as follows: an appropriate volume of siRNA (from 10 µM stock) was mixed with the desired CN formulation (from a 625 µg/ml stock) with pipetting up and down to ensure optimal mixing. The nioplex samples were incubated at room temperature for 30 min to allow the formation of transfection complexes.
For cellular uptake experiments including flow cytometry and fluorescent microscopy, AllStars AF488-labelled Negative Control siRNA (Qiagen, UK) was used to monitor transfection efficiency. For experiments that involved the GFP knockdown in copGFP-A549 cells, siGFP (IDT, Belgium) was used.
In vitro cellular uptake
To study the cellular uptake of nioplexes, A549 cells were seeded in 12 For this purpose, the media was removed and the cells were trypsinised, centrifuged and resuspended in FACS buffer (10% v/v FBS in PBS) and analysed on a FACS Canto flow cytometer (BD Biosciences; Oxford, UK). Upon acquisition, the cells were gated using forward scatter versus side scatter (FCS vs SSC) to eliminate dead cells and debris. Cells (10,000) were collected for each sample and the data analysed with DB FACS Diva software.
siRNA alone, CN alone, and untreated cells were used as controls. The final siRNA concentration after transfection was 10 nM. For qualitative uptake measurements, cells were prepared as described above and the cellular uptake of nioplexes were viewed using a Carl
Zeiss Axio-Imager Z1 microscope (Zeiss, Germany) under a 20X water immersion lens with a numeric aperture of 0.80. Fluorescence was excited using a mercury lamp and emission recorded using a fluorescein isothiocyanate (FITC) filter block (485/515-530nm). Analysis of images was carried out with AxioVision 4.8 software.
Silencing efficiency studies
copGFP-A549 cells preparation
For the GFP silencing evaluation, copGFP-A549 cells were seeded in 12-well plates at 1x10 (v/v) CO2 and 100% humidity.
Evaluating GFP silencing by FACS
To 
Statistical analysis
All experiments were performed in triplicate and one-way analysis of variance (ANOVA) was used to assess statistical significance. Tukey's multiple comparison test and t-test was performed for paired comparisons. The statistical analysis was performed using Minitab software version 17. A value of p<0.05 was considered to be statistically significant.
Results
Physiochemical characterisation of CN
CN prepared by microfluidics were assessed for their size, PDI, and ZP (Table 3 ). All the prepared formulations were small in size < 60 nm and had low particle size distribution as indicated by their PDI values (<0.2). As a result of using the cationic lipid DDAB, all the prepared formulations carried an overall positive ZP value. (Figure 1 ).
Cytotoxicity of CN on the A549 cell line
Toxicity of the CN formulations was assessed on A549 cells to quantify cell viability ( Figure   2 ). The cytotoxicity increased as a function of CN concentration. For all formulations, concentrations equal or below 78.13 µg/ml were well tolerated by cells, with 100% cells viability. CN concentration above 312.5 µg/ml induce significant (p<0.05) cytotoxicity. As a result, all the transfection experiments were carried out at CN concentrations less or equal to 78.13 µg/ml as a final concentration after transfection to avoid confounding vehicle related cytotoxicity with the gene silencing activity of siRNA. 
Uptake of siRNA nioplexes by A549 cells
To study the cellular uptake of siRNA encapsulated in CN formulations, A549 cells were treated with the various nioplexes prepared with AF488-labelled Negative Control siRNA.
The treated cells were analysed by fluorescence microscopy for qualitative analysis and with FACS for quantitative cellular uptake. Figure 3(B) ) confirming cellular uptake. However, the histogram images indicate a variation in the degree of the curve shift of the three formulations. To further analyse this variation, the percentage cellular uptake for each formulation was measured ( Figure 4 ) and found to be for formulations A and B 93.18 ± 2.10 % and 93.15 ± 0.74 %, respectively with no significant (p>0.05) difference between them. These percentages were significantly (p<0.05) higher than the uptake achieved using HiPerFect (80.08 ± 1.42 %). The percentage cellular uptake achieved with formulation C was 73.71 ± 0.14 %, which was significantly (p< 0.05) lower than formulations A, B, and HiPerFect. However, the uptake achieved with all three formulations and HiPerFect were significantly (p<0.05) higher than the siRNA uptake when the cells were treated with siRNA alone without any transfection agent.
A B Figure 3 (A) Fluorescent microscopic images (objective lens 20X) and (B) flow
cytometry histograms of A549 cell uptake when treated with nioplexes made with AF488-labelled siRNA. Images are representative of three independent images from each sample. The data present means ± standard deviation (n = 3).
Silencing efficiency studies
GFP silencing by FACS
To assess the GFP knockdown by siGFP delivered by the CN formulations, copGFP-A549 cells were transfected with various concentrations (10-100 nM) of siGFP using formulations A-C to investigate the effect of siRNA dose on transfection activity. siGFP concentrations greater than 100 nM were not evaluated in order to avoid possible off-target effects. The percentage of GFP expression was calculated compared against untreated cells as 100%. As can be seen in Figure 5 , all formulations were able to bring down the GFP expression with different percentages. Formulation A was the least effective in silencing GFP with a * * * * minimum value of GFP expression of 65.79 ± 9.16%, achieved using 50 nM siGFP. For formulation B, GFP silencing activity increased progressively with siGFP concentration. At 10 and 25 nM, the percentages of GFP expression were 78.53 ± 11.22 and 82.82 ± 13.12% respectively, which was not significantly (p>0.05) different from formulation A at the same concentration. However, when the siGFP concentration increased to 50 and 100 nM, the GFP expression was brought down to 40.19 ± 11.68 and 49.97 ± 15.05%, respectively, which was significantly (p<0.05) higher than formulation A at the same concentrations. A significant down-regulation of GFP expression was determined using formulation C in which the GFP expression was brought to about 30% compared to untreated cells at all siGFP concentrations.
This knockdown efficiency using formulation C was significantly (p<0.05) higher than the knockdown achieved using formulations A and B. For example, at 100 nM siGFP concentrations, the percentage of GFP expression achieved by formulations A-C were 74.58 ± 1.53, 49.97 ± 15.04, and 27.78 ± 16.51%, respectively, indicating a 3 and 2-fold higher siRNA transfection efficiency for formulation C compared with formulations A and B, respectively. These results for formulation C were almost the same as that for HiPerFect, where the percentage of GFP expression was around 35% at all siGFP concentrations used. In contrast, naked siGFP and mock transfection using all formulations showed minimal GFP down-regulation.
GFP silencing measured by Western blotting
To further confirm the results obtained above, the relative GFP levels of treated cells with different siGFP concentrations (10-100 nM) transfected with the three formulations (A-C) was evaluated in vitro in copGFP-A549 cells by Western blotting. Similar to FACS results, all three formulations were able to transfect the copGFP-A549 cells and down-regulate the GFP expression by siRNA. As can be seen in Figure 6 (A), formulation C was able to induce the highest GFP knockdown at all the concentrations used compared with formulations A and B. Moreover, mock transfection, naked siGFP, and scrambled negative control siRNA transfected via all formulations did not induce any GFP suppression, which indicates the effectiveness of the CN formulations and the specificity of the siGFP used. Semiquantification of the bands showed that the GFP expression was 18.79 ± 5.54% when the cells were transfected with 10 nM siGFP loaded in formulation C, while cells transfected with higher siGFP concentrations (25-100 nM) with formulation C had the same GFP expression (~ 10%). These results, achieved by formulation C, were comparable with the GFP inhibition achieved using HiPerFect where the GFP expression was about 10% at all concentrations used (10-100 nM) (Figure 6 (B) ). The percentage GFP expression in cells treated with 10 nM siGFP using formulation B was 64.83 ± 5.08%, while the GFP expression when the cells were transfected with higher concentrations (25-100 nM) was stable (~55%).
Formulation A results were comparable with those of formulation B where the GFP expression was 68.80 ± 6.18% using 10 nM siRNA, while cells transfected with 25 nM resulted in GFP expression of 55.19 ± 7.58%. However, higher concentrations of siGFP transfected with formulation A did not achieve higher inhibition of GFP expression. 
Discussion
siRNA has significant potential to act as a gene-specific therapeutic agent for the treatment of a wide range of diseases [24] . However, the clinical application of siRNA is limited by the development of effective delivery systems. NISV are gaining more interest as a drug delivery system for various therapeutic agents [18] . Previous work using formulations that combine non-ionic surfactants with phospholipids were used for the delivery of oligonucleotides [25] , and for siRNA [24] ; however, these formulations were a combination between liposomes and NISV.
The present work explored the potential of NISV as a delivery system for siRNA. Three different formulations were prepared by microfluidics and they were found to be monodisperse and small (<60 nm) which is a desirable characteristic for drug delivery systems to enhance the accumulation at the tumour site through the enhanced permeability and retention effect [26] . The prepared formulations A-C were shown to have good colloidal stability over two months at 25°C.
The cytotoxicity of the prepared formulations on the A549 cell line was measured to make sure any gene knock-down was caused by the siRNA used, rather than from any toxic effect of the delivery system. At concentrations less than 78.13 µg/ml, all the formulations were non-toxic to the cells and this was consistent with what was reported previously for NISV using other formulations [18] . All the following experiments that include siRNA transfection were carried out at a final concentration at or below this concentration.
The transfection efficiency of the formulations was evaluated as a measure of cellular uptake of siRNA. Cellular uptake analysis is a primary assay that helps to understand part of the transfection process and show the efficiency of the formulations to be internalised when they are in contact with the target cells. Gene knockdown by siRNA is an indication that the siRNA has been properly delivered by the vector. However, the transfection process sometimes involves a low number of cells which might be inadequate for gene therapy.
Therefore, one of the main objectives of this work was to achieve high percentages of target cell transfection with minimal toxic effects.
To test the effectiveness of formulations A-C in delivering siRNA into the cells and to quantify the cellular uptake, AF488-labelled siRNA was encapsulated into each of the three formulations and transfected into A549 cells. Fluorescent microscopy and flow cytometry were used to assess the cellular uptake. All three formulations were able to deliver the siRNA to the cells as indicated by the strong green fluorescent areas on the microscopy images and by the shift in the fluorescence histograms in the FACS results, compared to the untreated cells. Cellular uptake is influenced by different factors such as particle size, shape, surface charge, and chemistry of the nanoparticles [27] . Regarding the effect of particle size on nanoparticle cellular uptake, several studies reported that a 40-50 nm diameter is optimal to maximise the cellular uptake in certain mammalian cells [28, 29] . A lower degree of cellular uptake was noticed for particle sizes above and below this range [30] . In addition, cationic nanoparticles are usually taken up by the cells at a higher rate than anionic particles as a result of interaction of the positive charge with negatively charged domains on the cell membrane [31] . By analysing the characteristics of the CN formulations A-C, all three were carried positive charge and were within the desired size range. These favourable characteristics resulted in high cellular uptake for all three formulations, as can be seen in Following cellular uptake, an effective delivery system must promote endosomal release of siRNA into the cytoplasm for gene silencing [32] . To further examine the efficacy of our formulations in delivering siRNA into cells for the purpose of gene silencing, a series of gene silencing studies on GFP-producing A549 cells (copGFP-A549) to target GFP expression by siGFP were carried out. GFP is a protein that exhibits a bright florescence when exposed to light in the blue to ultraviolet range and is used as a marker of gene expression and protein targeting in intact cells and organisms [33] . CopGFP-A549 is a commercially available A549 cell line that is modified by the supplier to ensure they endogenously express copGFP. A decrease in GFP fluorescence in these cells after transfection indicates endosome release of the siGFP into their cytoplasm where the RNAi knockdown mechanism occurs. By monitoring any changes in fluorescence intensity of the GFP-producing cells after transfection with anti-GFP siRNA, the efficacy of the delivery system can be judged. Therefore, we analysed the copGFP-A549 cells by FACS after transfection with various concentrations (10-100 nM) of siGFP using formulations A-C, with HiPerFect as a positive control. By comparing the fluorescence of the transfected cells with untreated cells, an estimation of the transfection efficiency of the three formulations could be made. FACS analysis showed that all three formulations were able to downregulate GFP expression to varying degrees. Formulation C was able to suppress GFP expression using siGFP by more than 70% compared to the untreated cells at all the siRNA concentrations, which was comparable with the GFP knockdown achieved using HiPerFect. The GFP knockdown using formulation C was superior to the GFP knockdown achieved by formulations A and B. These GFP knockdown results using the CN formulations were higher than the GFP knockdown achieved with other delivery systems. For example, Zhu et al. designed multifunctional polymeric micelles for siRNA delivery and targeting GFP production in copGFP-A549 cells.
With their system, the maximum GFP knockdown they achieved was about 55% compared to untreated cells after one transfection as shown by FACS [34] . Zhou et al. were able to achieve a maximum of 65% of GFP silencing in human breast cancer cells (MDA-MB-231) using 100 nM siGFP transfected through their SPANosome vesicles [24] .
To further understand the transfection efficiency of the CN formulations, we analysed the Together with the cytotoxicity data, these results also suggests that downregulated gene expression due to non-specific toxic effects of the formulations used can be excluded, since no effect on GFP expression was obvious when the formulations alone (mock) were used as controls which confirms that the observed GFP suppression was due to siGFP transfection instead of vehicle-related cytotoxicity.
It has been reported in the literature that the transfection efficiency by lipid-based nanoparticles strongly depends on the chemical composition of the lipids used [35, 36] . The data above confirms an efficient delivery of bioactive siRNA into the cytosol after cellular uptake and successful release of nanoparticles or siRNA from endosomes or lysosomes can be concluded as a result of the GFP knockdown. Since it was notable that formulation C induced higher gene downregulation than formulations A and B using the same siRNA concentrations, the variations in the transfection efficiency between the formulations could be explained, in part, by the different endosomal escape ability of the lipids used [37] . Although formulation C showed the least cellular uptake compared to the other formulations, this superiority in GFP knockdown compared to formulations A and B suggests that the presence of Tween 85 enhances the endosome escape for formulation C at a higher rate than the MPG in formulations A and B.
From all the non-ionic surfactant types, Tween surfactants are one of the most commonly used in the pharmaceutical industry. It includes Tween 20, Tween 60, Tween 80, and Tween 85 depending on the hydrophobic tail present. An attractive property in the structure of all the Tween surfactants is the presence of the hydrophilic polyoxyethylene chain which has been shown to possess a functional interaction with nucleic acids and is used as a gene transfer helper [38] . Endosome escape is one of the major barriers for efficient gene delivery. Tween surfactants are believed to have a fusogenic property similar to dioleoylphosphatidylethanolamine (DOPE), which is one of the most commonly used helper lipids in liposome formulations to facilitate endosome escape of liposomes and its nucleic acids cargo into the cytosol [39, 40] . From all the Tween surfactant types, Tween 85 is shown to have the highest efficacy when used with NISV for DNA delivery in which the particles formed were proven to have the highest endosome escape compared to NISV prepared with other Tween surfactants [38] . For all these reasons, the presence of T85 in formulation C was believed to enhance endosome release of the siGFP into the cytosol, where the RNAi mechanism occurs, at a higher rate than formulations A and B, which contributes to the enhanced silencing efficiency of the GFP expression.
To our knowledge, this is the first report on the use of NISV prepared by microfluidics for the delivery of siRNA. The surfactant vesicles therefore could prove a superior technology platform for therapeutic siRNA delivery. The present work demonstrates that our CN can be used to effectively deliver siRNA in vitro. Future work including cellular trafficking and in vivo activity evaluation are currently under investigation.
Conclusions
Here, for the first time the development of CN prepared by microfluidics for a siRNA delivery was reported. The formulations prepared possessed favourable physical characteristics and mediated efficient cytosolic delivery of siRNA. From the formulations tested, formulation C that was composed of Tween 85 as a non-ionic surfactant, showed superiority over the other two formulations, composed with MPG as the surfactant. The transfection efficiency of formulation C was shown to be comparable with the cationic transfection reagent, HiPerFect. In conclusion, these novel vectors constitute promising agents for delivery of siRNA and deserve further investigation.
